Abstract
Bone-targeting drug delivery systems have been rapidly developed to increase drug efficacy and safety for musculoskeletal diseases in the past decades. Bone-targeting drug delivery is mainly based on ligands that have hydroxyapatite affinity. We previously reported a pyrophosphorylated cholesterol ligand-based bone-targeting liposome formulation for the treatment of bone fracture delayed union. Different from traditional bone-targeting ligands: bisphosphonates tetracyclines and polyanion peptides. Pyrophosphorylated cholesterol has no intrinsic pharmacological effects and can be naturally degraded into metabolites (both pyrophosphate and cholesterol are substances that naturally exist in the body), leading to minimal safety concerns. Pyrophosphorylated cholesterol is not only biodegradable, but it also provides strong bone affinity, which could target different bone substructures/surfaces, further improving drug delivery efficiency in vivo. Here, we describe the synthesis protocol of pyrophosphorylated cholesterol and a reverse-evaporation-based formulation protocol of pyrophosphorylated-cholesterol-modified bone-targeting liposomes for hydrophilic drug encapsulation. We also provide instructions for the bone-targeting property evaluation of the pyrophosphorylated-cholesterol-modified liposome in vitro and in vivo. Our system has wide applications and has already been used to study drug treatment for fracture delayed union and nonunion. As a promising bone-targeting drug delivery system, our system may be extrapolated to clinical applications of other bone anabolic agents for different bone diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chen F, Jia Z, Rice KC et al (2013) The development of dentotropic micelles with biodegradable tooth-binding moieties. Pharm Res 30:2808–2817
Huang L, Wang X, Cao H et al (2018) A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice. Biomaterials 182:58–71
Liu Y, Jia Z, Akhter MP et al (2018) Bone-targeting liposome formulation of Salvianic acid a accelerates the healing of delayed fracture Union in Mice. Nanomedicine 14:2271–2282
Rotman SG, Grijpma DW, Richards RG et al (2018) Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J Control Release 269:88–99
Sun S, Tao J, Sedghizadeh PP et al (2021) Bisphosphonates for delivering drugs to bone. Br J Pharmacol 178:2008–2025
Wang D, Miller S, Sima M et al (2003) Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 14:853–859
Wang D, Miller SC, Kopeckova P et al (2005) Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 57:1049–1076
Xie Y, Liu C, Huang H et al (2018) Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment. Drug Deliv Transl Res 8:1090–1102
Zhou L, Wu H, Gao X et al (2020) Bone-targeting liposome-encapsulated Salvianic acid a improves nonunion healing through the regulation of HDAC3-mediated endochondral ossification. Drug Des Devel Ther 14:3519–3533
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Liu, Y., Jia, Z., Ma, L., Wang, D. (2023). Pyrophosphorylated-Cholesterol-Modified Bone-Targeting Liposome Formulation Procedure. In: D'Souza, G.G., Zhang, H. (eds) Liposomes. Methods in Molecular Biology, vol 2622. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2954-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2954-3_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2953-6
Online ISBN: 978-1-0716-2954-3
eBook Packages: Springer Protocols